Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Cell Medica Announces Treatment of First Pediatric Patient in ASPIRE Trial

Published: Tuesday, July 09, 2013
Last Updated: Tuesday, July 09, 2013
Bookmark and Share
ASPIRE Trial expected to complete in early 2015.

Cell Medica has announced the treatment of the first patient in the ASPIRE Trial, an early stage Phase I/II clinical study investigating the safety and efficacy of Cytovir™ ADV for the treatment of adenovirus infections in immunosuppressed pediatric patients following bone marrow transplantation.

The ASPIRE Trial represents a collaborative R&D project among Cell Medica, UCL Institute of Child Health and the Great Ormond Street Hospital for Children.

The project is funded in part by a grant from the Technology Strategy Board, the UK’s innovation agency.

Cytovir ADV is under development as a new way to treat adenovirus infections in pediatric patients following allogeneic hematopoietic stem cell (bone marrow) transplantation.

These patients are profoundly immunosuppressed for a period of three to six months after the procedure and therefore highly vulnerable to serious infections.

In certain high risk pediatric groups following bone marrow transplantation, there is a mortality risk of up to 30% for patients developing adenovirus infections.

No drug is currently approved for the treatment of adenovirus infections in this patient group.

Cytovir ADV is comprised of naturally occurring T lymphocyte cells (T cells) which demonstrate immune response functions when exposed to adenovirus antigens.

The ASPIRE Trial will explore whether adenovirus-specific T cells can be infused in pediatric patients to reconstitute immediate and long-lasting immunity against the virus, thereby potentially avoiding the medical costs, hospitalization and mortality associated with adenovirus infections in this patient group.

The ASPIRE Trial will include up to 15 patients and is expected to complete in early 2015. The Chief Investigator is Dr. Waseem Qasim of the UCL Institute of Child Health.

Extending the pipeline of patient-specific T cell therapies for immune reconstitution
Cytovir ADV is an extension of Cell Medica’s T cell products being investigated for infections in patients following bone marrow transplantation. Cell Medica’s lead product, Cytovir CMV, is currently being tested in two randomized controlled studies across 15 transplantation centres in the UK.

Gregg Sando, CEO of Cell Medica, commented: “The ASPIRE Trial initiates the clinical development of Cytovir ADV in pediatric patients following bone marrow transplantation. Along with Cytovir CMV, we are developing the adenovirus treatment to expand our cell therapy solutions to include two of the most important viral infections in patients following bone marrow transplantation. The clinical research partnership with the UCL Institute of Child Health and the Great Ormond Street Hospital has been very productive in allowing us to identify a high risk group of pediatric patients who could gain particular benefit from an effective and non-toxic antiviral treatment. The support of the Technology Strategy Board was instrumental to provide the platform for this successful collaboration.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More Than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Cell Medica Announces Senior Management Appointments
Key appointments to Cell Medica's senior executive team.
Friday, March 08, 2013
Cell Medica Secures £17 Million Equity Investment
Investment to establish US operations and fund cell therapy development.
Monday, August 06, 2012
Cell Medica and UCL Institute of Child Health Receive Grant Funding
Company receives grant funding from the Technology Strategy Board for ASPIRE.
Monday, March 05, 2012
Scientific News
The Rise of 3D Cell Culture and in vitro Model Systems for Drug Discovery and Toxicology
An overview of the current technology and the challenges and benefits over 2D cell culture models plus some of the latest advances relating to human health research.
Grant Supports Project To Develop Simple Test To Screen For Cervical Cancer
UCLA Engineering announces funding from Bill and Melinda Gates Foundation.
Injecting New Life into Old Antibiotics
A new fully synthetic way to make a class of antibiotics called macrolides from simple building blocks is set to open up a new front in the fight against antimicrobial drug resistance.
Insight into Bacterial Resilience and Antibiotic Targets
Variant of CRISPR technology paired with computerized imaging reveals essential gene networks in bacteria.
Advancing Protein Visualization
Cryo-EM methods can determine structures of small proteins bound to potential drug candidates.
Alzheimer’s Protein Serves as Natural Antibiotic
Alzheimer's-associated amyloid plaques may be part of natural process to trap microbes, findings suggest new therapeutic strategies.
Slime Mold Reveals Clues to Immune Cells’ Directional Abilities
Study from UC San Diego identifies a protein involved in the directional ability of a slime mold.
How Do You Kill A Malaria Parasite?
Drexel University scientists have discovered an unusual mechanism for how two new antimalarial drugs operate: They give the parasite’s skin a boost in cholesterol, making it unable to traverse the narrow labyrinths of the human bloodstream. The drugs also seem to trick the parasite into reproducing prematurely.
Illuminating Hidden Gene Regulators
New super-resolution technique visualizes important role of short-lived enzyme clusters.
Supressing Intenstinal Analphylaxis in Peanut Allergy
Study from National Jewish Health shows that blockade of histamine receptors suppresses intestinal anaphylaxis in peanut allergy.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!